Skip to main content
. Author manuscript; available in PMC: 2010 Apr 15.
Published in final edited form as: Cancer Res. 2009 Apr 7;69(8):3537–3544. doi: 10.1158/0008-5472.CAN-08-3386

Figure 5. GCC-specific immunization does not amplify tumorigenesis in genetic and inflammatory models of colorectal cancer.

Figure 5

A-C, APCmin/+ C57BL/6 mice were immunized with Control-AV or GCC-AV and boosted sequentially with RV and VV at 28 day intervals beginning at 4 weeks of age. Two weeks after the final immunization intestines were collected, examined by histology (A) and tumor burden was quantified in small (B) and large intestine (C). Error bars indicate 95% confidence intervals (# P >0.05 two-sided Welch's t test). D-F, female C57BL/6 mice were immunized with Control-AV or GCC-AV and boosted sequentially with RV and VV at 28 day intervals beginning at 6 weeks of age. The procarcinogen AOM was administered 3 days before the final immunization. Seven days later, 3 cycles of DSS were initiated with 14 days of by histology for epithelial damage and inflammation. # P >0.05 Bonferroni's multiple comparison test.